FDA priority review of BLA for beti-cel gene therapy for patients with beta-thalassemia.
Beti-cel is a potentially transformative gene therapy for adult, adolescent and pediatric patients with beta-thalassemia across all genotypes who require regular red blood cell (RBC) transfusions. If approved, beti-cel will be the first one-time treatment that addresses the underlying genetic cause of disease for patients living with beta-thalassemia in the U.S.—offering an alternative to regular RBC transfusions and iron chelation therapy. The agency has set a Prescription Drug User Fee Act (PDUFA) goal date of May 20, 2022.
The BLA for beti-cel is based on data from bluebird bio’s Phase III studies HGB-207 (Northstar-2) and HGB-212 (Northstar-3), the Phase 1/II HGB-204 (Northstar) and HGB-205 studies, and the long-term follow-up study LTF-303. Together, these studies represent more than 220 patient-years of experience with beti-cel. As of March 9, 2021, the results include a total of 63 pediatric, adolescent and adult patients, including long-term efficacy and safety results in two patients with more than seven years follow-up. Additional data through August 2021 will be presented at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition, taking place December 11-14, 2021.
Related news and insights
Clover Biopharmaceuticals, Ltd. announced positive data from its ongoing Phase III study evaluating Clover’s SCB-2019 (CpG 1018/Alum) as a universal COVID-19 booster vaccine candidate
NICE recommendation for upadacitinib as an option for treating active ankylosing spondylitis that is not controlled well enough with conventional therapy in adults, only if: i. tumour necrosis factor (TNF)-alpha inhibitors are not suitable or do not control the condition well enough and iithe company provides upadacitinib according to the commercial arrangement
Atezolizumab is recommended for use within the Cancer Drugs Fund as an option for adjuvant treatment after complete tumour resection in adults with stage 2 to 3a non-small-cell lung cancer (NSCLC) whose: i. tumours have the programmed cell death ligand 1 (PD L1) biomarker expression on 50% or more of their tumour cells and ii. whose disease has not progressed after platinum-based adjuvant chemotherapy